EUCAST in vitro activity of Ibrexafungerp (SCY-078) against C. auris isolates; comparison with activity against C. albicans and C. glabrata and with that of six comparators.
Sign Up to like & getrecommendations! Published in 2019 at "Antimicrobial agents and chemotherapy"
DOI: 10.1128/aac.02136-19
Abstract: Ibrexafungerp (SCY-078) is a novel first-in-class antifungal agent targeting the glucan synthase. C. auris is an emerging multidrug resistant species that has caused outbreaks on five continents. We investigated the in vitro activity of ibrexafungerp… read more here.
Keywords: scy 078; activity; albicans glabrata; ibrexafungerp scy ... See more keywords
In Vitro Antifungal Activity of Ibrexafungerp (SCY-078) Against Contemporary Blood Isolates From Medically Relevant Species of Candida: A European Study
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Cellular and Infection Microbiology"
DOI: 10.3389/fcimb.2022.906563
Abstract: Background Ibrexafungerp (SCY-078) is the newest oral and intravenous antifungal drug with broad activity, currently undergoing clinical trials for invasive candidiasis. Objective The aim of this study was to assess the in vitro activity of… read more here.
Keywords: ibrexafungerp scy; ibrexafungerp; candida; blood isolates ... See more keywords